Project Grant HT94252410299

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) totaling $352,275 provides funding to the Regents of the University of Minnesota to conduct research aimed at developing novel, safe, and effective agents for the prevention and therapy of lung cancer with co-occurring KRAS and LKB1 mutations. The key objectives are to: Assess the safety and efficacy of MITOMET, a mitochondria-targeted metformin analog, in...

This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $148,050.00 to Weill Medical College of Cornell University to conduct research on the role of the APOBEC3 family of enzymes in driving genomic instability and mutagenesis in lung cancer. The research aims to identify the specific APOBEC3 paralogs responsible for lung cancer mutagenesis, evaluate methods to accurately measure APOBEC3 activity, and explore how APOBEC3 enzymes regulate...

This Project Grant award, funded by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) program, aims to elucidate the role of thiol reductive stress in lung cancer growth and metastasis. The $140,130 award to The General Hospital Corporation (Massachusetts General Hospital) will support research to investigate how the precise induction of reductive stress, regulated by the transcriptional regulator NRF2, impacts mitochondrial metabolism and contributes to the...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), aims to define the signatures of epigenetic sensitization that predispose to lung cancer development in a mouse model. The $234,730 award, granted on July 9, 2024, will support a 2-year research project at Yale University to: Define the transcriptional and epigenetic phenotypes of normal lung tissue in mice with epigenetic sensitization to lung cancer....

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), is supporting the development of a high-sensitivity, high-specificity lung cancer subtyping diagnostic test by Orbit Genomics, Inc. The $1,999,108 award will enable Orbit Genomics to: 1) obtain patient blood samples with known lung cancer subtypes to train their diagnostic test, 2) upgrade their microsatellite allelotyping and AI-based classification...

The National Cancer Institute (NCI) awarded a 5-year, $548,915 Project Grant under the federal Cancer Cause and Prevention Research (CFDA 93.393) program to the Fred Hutchinson Cancer Center in Seattle, Washington. This grant supports research to better understand the biological role of the stress-activated protein kinase (SAPK) pathway as a tumor suppressor in small cell lung cancer (SCLC). The project aims to leverage cellular models, genetically engineered mouse models, and human tumor...

The National Cancer Institute (NCI) awarded a $608,491 Project Grant under the Cancer Biology Research (CFDA 93.396) program to Northwestern University. The grant supports a 5-year research project investigating the role of the mitochondrial enzyme malate dehydrogenase 2 (MDH2) in lung tumor growth and progression. The project aims to use mouse models to explore how MDH2 and mitochondrial NAD+ regeneration impact tumor initiation, growth, and normal lung cell function. Key experiments will...

The National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), awarded a $744,575 project grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to study the role of Long Interspersed Element-1 (LINE-1 or L1) activity in the development of high-grade serous ovarian cancer (HGSOC). The project aims to define the genomic and biologic impact of L1 activity in fallopian tube epithelial cells, as well as...

This $566,523 federal Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will support research to identify interception targets in persistent lung premalignant lesions (PMls) that are at high risk of progressing to lung cancer. The awardee, the University of Colorado-Denver, will use a reverse translational approach to: 1) identify interception targets in the persistence profile in clinical trial biopsies, 2)...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, is focused on uncovering the core mechanisms driving lineage plasticity in EGFR-mutant lung adenocarcinoma (LUAD). The $631,156 award will fund a 5-year research project conducted by the Icahn School of Medicine at Mount Sinai to systematically investigate the genetic, transcriptomic, and epigenomic changes underlying the transformation of LUAD to the more...